A Phase I, Open-Label, Dose-Escalation Study of CC-11006 In Subjects With Low- or Intermediate-1 Risk Myelodysplastic Syndromes

Stopped early · Phase 1

Conditions studied: Myelodysplastic Syndrome

In brief

A Phase I, Open-Label, Dose-Escalation Study of CC-11006 In Subjects With Low- or Intermediate-1 Risk Myelodysplastic Syndromes.

Key facts

Study ID

NCT00458159

Run by

Celgene

People needed

34

Starts

2007-05-01

Expected to finish

2008-12-01

Last updated by the study team

2019-12-13

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• H. Lee Moffitt Cancer Center and Research Institute — Tampa, Florida, United States
• Indiana University Medical Center — Indianapolis, Indiana, United States
• Center for Cancer and Blood Disorders — Bethesda, Maryland, United States
• New York Presbyterian Hospital-Weill Cornell Medical College — New York, New York, United States
• Wake Forest University School of Medicine Bowman Gray Campus, Comprehensive Cancer Center — Winston-Salem, North Carolina, United States
• The Cleveland Clinic Foundation — Cleveland, Ohio, United States
• MD Anderson Cancer Center — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.